Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 351 to 375 of 2529

TitleReference numberPublishedLast updated
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTG701
Biodegradable subacromial spacer insertion for rotator cuff tearsHTG702
Extracorporeal carbon dioxide removal for acute respiratory failureHTG703
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Jaundice in newborn babies under 28 daysCG98
Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home)QS210
Ranibizumab for treating diabetic macular oedemaTA274
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditionsHTG699
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Stroke rehabilitation in adultsNG236
Daridorexant for treating long-term insomniaTA922
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Percutaneous deep venous arterialisation for chronic limb-threatening ischaemiaHTG698
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Thyroid disease: assessment and managementNG145
Virtual ward platform technologies for acute respiratory infections: early value assessmentHTG697
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915

Results per page

  1. 10
  2. 25
  3. 50
  4. All